Advertisement
Using its proprietary extraction and quantification methods, RosettaGenomics is now advancing the development of a blood-based test which willutilize microRNAs to detect patients with colon cancer.
Advertisement
"This study further validates our understanding that microRNAs may beused as clinical biomarkers for a wide range of indications, both throughinvasive and non-invasive methods," noted Dr. Dalia Cohen, Chief ScientificOfficer of Rosetta Genomics. "The results of this study are the basis of oneof our development programs to detect colon cancer via microRNAs identifiedin serum. I believe our strong scientific capabilities will continue toproduce exciting studies, which we will share once available."
The paper, "Serum MicroRNAs are Promising Novel Biomarkers" is nowavailable on PLOS One website onhttp://dx.plos.org/10.1371/journal.pone.0003148
About microRNAs
MicroRNAs (miRNAs) are recently discovered, naturally occurring, smallRNAs that act as master regulators and have the potential to form the basisfor a new class of diagnostics and therapeutics. MicroRNAs have been shown tohave different expression profiles in various pathological conditions. As aresult, these differences may provide for a novel diagnostic strategy formany diseases.
About Rosetta Genomics
Rosetta Genomics (Nasdaq: ROSG) is a leader in the field of microRNA.Founded in 2000, the company's integrative research platform combiningbioinformatics and state-of-the-art laboratory processes has led to thediscovery of hundreds of biologically validated novel human microRNAs.Building on its strong IP position and proprietary platform technologies,Rosetta Genomics is working on the application of these technologies in thedevelopment of a full range of microRNA-based diagnostic and therapeutictools, focusing primarily on cancer and various women's health indications.The first test based on the company's technology, differentiating squamousfrom non squamous non small cell lung cancer, is now approved throughColumbia University Medical Center's High Complexity Molecular PathologyLaboratory. In Addition, the company expects two additional microRNAdiagnostic tests applying its technology will be validated and submitted forregulatory approval by licensed clinical laboratories in the United States in2008.
Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta's futureexpectations, plans and prospects, including without limitation, statementsrelating to the potential of microRNAs extracted from blood to serve aseffective biomarkers for a wide range of indications, including colon cancer,the role of microRNAs in human physiology and disease, the potential ofmicroRNAs in the diagnosis and treatment of disease, and the timing of launchof the first diagnostic tests applying Rosetta's microRNA technologyconstitute forward-looking statements for the purposes of the safe harborprovisions under The Private Securities Litigation Reform Act of 1995. Actualresults may differ materially from those indicated by these forward-lookingstatements as a result of various important factors, including risks relatedto: Rosetta's approach to discover and develop novel diagnostics andtherapeutic tools, which is unproven and may never lead to marketableproducts or services; Rosetta's ability to fund and the results
